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the comparable estimates would be C$11.65/person (HC) and C$0.84/person (FC). 
ICER of HD vs IIV3 was C$190/QALY with HC approach and C$3,106/QALY with FC. 
In comparison, the difference of ICERs of IIV4 vs IIV3 was small - $16,232/QALY (HC) 
and C$19,028/QALY (FC). Exclusion of productivity costs of mortality had minimal 
impact with similar ICERs to FC method. CONCLUSIONS: The differences in ICERs of 
IIV4 vs IIV3 with HC method, FC method or no productivity costs of mortality were 
significantly narrower than those of HD vs IIV3. Relative vaccine efficacy against 
influenza-related deaths to IIV3 was a key driver of productivity costs; therefore, 
choice of methods could be crucial with massively different results. Those conclu-
sions were robust to alternative friction periods and elastic factors.
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OBJECTIVES: Colombia is an endemic country for malaria. Burden of disease and 
costs estimations are scarce. The aim of this analysis is to estimate the burden 
of disease and the diagnosis and care costs of malaria, from the surveillance 
data. METHODS: A malaria transmission model was built from an age-dependent 
Markov process, to simulate the morbidity and mortality of the malaria infection 
in the Colombian population from the national surveillance system and other 
literature. The model included a birth cohort followed up to their life expectancy. 
We estimated the number of malaria, malaria complicates and death cases in the 
cohort during the life span. From the official malaria diagnosis and treatment 
guidelines we captured the frequency of use for all cost items and calculated 
the cost per patient from the tariff manual and international prices. Cost esti-
mation was carried out from the third payer perspective. We estimated the dis-
ability adjusted life years (DALYs) and diagnosis and care costs for each malaria 
case and entire population during 2012 splitting by different Plasmodium specie. 
All costs were reported in 2012 American dollars (exchange rate of US$ 1768.23.
per COP). RESULTS: During 2012 we estimated 65.448 cases and 32 deaths due 
to malaria. The 71.7% of cases were due to P. vivax and 27.0% by P. falciparum. 
Complications were presented in 1% of all cases. All malaria cases sum a burden 
of disease of 1902 DALYs (mainly due to year of life lost-YLL, 1878). Total estimated 
cost was US$936.253, 5% of them due to complicated malaria. CONCLUSIONS: 
Burden and costs of disease due to malaria in Colombia are relevant in spite of 
availability of effective preventive measurements. Cost-effectiveness of different 
public health interventions should be evaluate for the decision making process 
and this model will be a valuable input for that task.
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OBJECTIVES: Data on costs of surgical site infections (SSIs) following ambulatory 
surgery are sparse, despite a shift towards outpatient procedures. We determined 
the impact of serious and non-serious SSIs on healthcare costs following common 
ambulatory surgical procedures throughout the cost distribution. METHODS: We 
conducted a retrospective cohort study of persons < 65 years coded for cholecys-
tectomy, breast-conserving surgery (BSC), anterior cruciate ligament reconstruction 
(ACL), or hernia repair from 12/31/2004–12/31/2010 using commercial insurer claims 
data. SSIs within 90 days after surgery were identified by ICD-9-CM diagnosis codes. 
Infections during inpatient hospitalization or resulting in surgical treatment were 
considered serious. Quantile regression controlling for underlying illness, operative 
variables, demographics, and surgical facility type was used to examine the impact 
of serious and non-serious SSIs on 180-day healthcare costs. RESULTS: The inci-
dence of serious/non-serious SSIs (# procedures) were 0.8%/0.2% after ACL (21,062), 
0.5%/0.3% after cholecystectomy (57,750), 0.6%/0.5% after hernia repair (60,681), and 
0.8%/0.8% after BCS (42,489). Serious SSIs were associated with significantly higher 
costs than non-serious SSIs for ACL, cholecystectomy, and hernia repair at all points 
examined in the cost distribution. For BCS, serious SSIs were associated with sig-
nificantly higher costs at the upper end (> = 80th percentile) of the cost distribution. 
The ratio of adjusted total costs for individuals with serious SSI vs. no SSI increased 
for both cholecystectomy and hernia repair as the total cost increased (3.2 for chol-
ecystectomy with serious SSI/no SSI at the 70th percentile of costs, up to 4.9 at the 
95thpercentile). CONCLUSIONS: SSIs, particularly serious infections resulting in 
hospitalization or surgical treatment, were associated with significantly increased 
healthcare costs after 4 common surgical procedures performed in inpatient and 
ambulatory settings. Quantile regression illustrated the impact of serious SSIs on 
healthcare costs across the distribution of costs, especially at the upper end of the 
cost distribution.
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OBJECTIVES: Antibiotic resistance (ABR) poses a threat to public health in the United 
States (US). The Centers for Disease Control and Prevention has identified three 
ABR urgent threats (defined as potential clinical and economic impact, transmis-
sibility, available treatment, barriers to prevention): Clostridium difficile (C. diff), 
carbapenem-resistent Enterobacteriaceae (CRE), and Neisseria gonorrhoeae (N. gon-
orrhoeae). Limited data exist which document ABR-related burden in the context 
of inpatient care. This study examines length of stay (LOS) and costs associated 
with ABR urgent threat-related hospitalizations in the US. METHODS: Using the 
2001-2012 Healthcare Cost and Utilization Project’s Nationwide Inpatient Sample 
databases, nationally-representative surveys of US hospitalizations, we identified 
hospitalizations with a diagnosis code indicating an urgent ABR threat. LOS and 
societal perspective. Replacing IIV3 with IIV4 would result a net societal budget 
impact of over C$3 million. The ICER of IIV4 vs IIV3 is C$20,733 per QALY gained 
from healthcare perspective and societally C$16,232 per QALY gained. At $50,000 
per QALY gained threshold, 100% and 93.8% of PSA simulations were cost-effective 
for HD and IIV4, respectively, from healthcare perspective, and 95.3% for IIV4 from 
societal perspective. HD becomes a dominant alternative when long-term care costs 
are considered. CONCLUSIONS: Both HD and IIV4 are expected to reduce influenza-
associated morbidity and mortality, and are cost-effective in the studied population 
comparing to IIV3; however, IIV4 is extended dominated by HD. Those conclusions 
were proven to be robust in sensitivity analyses.
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OBJECTIVES: Access to effective, low cost antiretrovirals (ARVs) is a public health 
imperative. This study compared ARV approvals and prices in Saudi Arabia (SA) 
and the United States (US) in 2014. METHODS: US Food and Drug Administration 
(FDA) ARV drug approvals data were collected from the FDA website. Likewise, 
ARV drug approvals and prices in SA were collected from the Saudi Food and Drug 
Administration (SFDA) website. ARV drug prices data were also collected from the 
World Health Organization (WHO) website. Descriptive analysis and paired t-test 
were performed. Statistical significance was set up at 0.05% RESULTS: In 2014, there 
were 27 ARVs and 9 fixed-dose combinations of ARVs approved by the FDA. The WHO 
listed 22 ARV single active ingredients and 16 combinations. Overall, 29.6% of the 
single active ingredients and 33.3% of the combinations approved by the FDA were 
marketed in SA. The FDA approved generic ARVs for 18.5% of the single active ingre-
dients and for 22.2% of the combinations. The WHO listed generic ARVs for 31.8% of 
the single active ingredients and 100% of the combination drugs. No generic ARV 
drugs were approved by the SFDA. Price data were available for 13 drugs. ARV drug 
prices in SA were in median 21.14 times higher than the ARV drug prices listed by the 
WHO (range 2.2 - 99.8 times) (p< 0.0001). CONCLUSIONS: Less than one third of the 
ARV drugs approved by the US FDA were marketed in SA in 2014. Prices in SA were 
significantly higher than prices listed by the WHO. Lack of SFDA approved generic 
ARVs may explain the price difference. Approvals of low cost generic ARVs remains 
a public health priority in SA to improve quality of life of HIV patients in the country.
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OBJECTIVES: To evaluate the cost of influenza vaccination, the sources of financing, 
and drug cost compared to the cost of vaccination in Ukraine. METHODS: We used 
the statistic data of the MoH of Ukraine, data about the rate of influenza vaccina-
tion. Comparative analysis of retrospective data on consumption of drugs and the 
cost of influenza vaccine. RESULTS: Vaccination against influenza and other acute 
respiratory infections (ARI) are not included in the list of obligatory vaccinations and 
not funded by the state, partially it funded from local budgets in Ukraine. During 
2009-2010 flu had pandemic status, but the number of vaccinated people was mini-
mal. It has been vaccinated 239104 people, among them the expense of businesses 
- 94546 (39.5%), local budgets - 106498 (44.5%) and patient funds - 38060 (15.9%). Only 
2.18% people over 60 years were vaccinated, but this category represents 15.9% of 
the total population. We conducted that average cost of flu vaccination was 101,0 
UAH (1 USD = 16,5 UAH). The average cost of ambulatory treatment per patient 
was 241,1 UAH, it was 2,4 times more than the vaccination cost Analysis of sales 
of drugs used for treatment of flu and ARI showed: NSAIDS were spent 118,8 mln. 
UAH., Expectorants - 275,3 mln., Antibiotics – 218,1 mln., but the cost of vaccines 
were 23,2 mln. UAH. The comparison showed that the cost of drugs for the treatment 
of influenza and ARI were at 26.4 times more than vaccines. CONCLUSIONS: We 
evaluated the high rate of incidence of influenza, low rate of influenza vaccination 
in 2009, a low percentage of vaccination of health-risk groups (for example, 60 +), the 
high cost on drugs to treat the flu and ARI. It confirmed the economic expediency 
of using influenza vaccine in Ukraine.
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OBJECTIVES: Although employment rate is lower in the elderly population, different 
methods valuing productivity loss can yield contrasting incremental cost-effective-
ness ratios (ICER). This research aims to compare the impact of human capital (HC) 
and friction cost (FC) methods on productivity costs and incremental cost-effective-
ness ratios (ICERs) of replacing IIV3 with either high dose (HD) or quadrivalent (IIV4) 
among adults aged 65 and over in Ontario. METHODS: Population-level influenza 
outcomes from either Ontario or Canada with provincial wage data set were used 
to calculate the productivity loss due to physician visits, ED visits, hospitalizations 
and premature deaths. Vaccines efficacies were extracted from clinical studies and 
published literatures. HC and FC utilized discounted life expectancy and 90-day 
friction period, respectively. Alternative friction periods and elasticity factors were 
analyzed. RESULTS: With IIV3 under the current Universal Influenza Immunization 
Program (UIIP), the productivity costs due to influenza-related premature mortality 
is C$11.92/person and C$0.86/person with HC and FC approach, respectively. Those 
per person for HD in place of IIV3 would be C$9.13 (HC) and C$0.65 (FC); for IIV4, 
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 1 – A 3 0 7  A235
OBJECTIVES: HCV infection in Egypt is one of the highest in the World. The objective 
of the study is to support Egyptian decision makers by comparing different treat-
ment rates with the recent approved Hep C antiviral agents, and its implications on 
prevalence progress and associated costs. METHODS: The analysis was based on 
a 17-year Markov model.Patients would progress through the various HCV stages 
from F0 to F3 followed by cirrhosis. Following cirrhosis to other progressive stages 
up to hepatocellular carcinoma and liver related death. Patients could be cured 
spontaneously in state F0 or as a result of antiviral therapy in any state from F0 to 
cirrhosis at a cure rate of 92% in stages F0-F3 and a cure rate of 80% in the stage of 
cirrhosis. Cured patients would transition to the mortality risk of the age-matched 
general population. In each cycle, new incident patients were also introduced at a 
rate of approximately 128,000 or 2%. RESULTS: Treating 8% of the infected cases 
each year (450K viremic cases/year) would bring the prevalence to 1 million by 2030. 
A treatment rate of 1% (65Kcases/yr) or 5% (300Kcases/yr) would bring the preva-
lence to 5.5 million and 2.5 million respectively by 2030. Total annual costs would 
start at $1.3Billion in the first year of treatment for the 8% treatment rate but would 
decrease to $580million/yr by 2030. The 5% and 1% rates would start at $900million 
& $550million. CONCLUSIONS: A treatment rate of 450Kcases/yr would bring the 
prevalence to 1 million by 2030. Costs would be significantly high during the first 
5 years, but eventually would dop as the disease burden decreases. Alternative 
scenarios wouldn’t eliminate the disease by 2030. A screening policy need to be 
in place & health infrastructure assessed in preparation for the rising numbers of 
patients receiving treatment
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OBJECTIVES: To determine (1) the cost of hospitalization and 1-week post-dis-
charge, (2) the difference between estimated costs and the Philippine Health 
Insurance Corporation (PhilHealth) pneumonia case rate payments, and (3) the 
economic burden of community-acquired pneumonia (moderate and high-risk, 
CAP-MR and CAP-HR, respectively) among patients aged > 19 years old in the 
Philippines. METHODS: The study involved two tertiary private hospitals in the 
Philippines. Using the societal perspective, out-of-pocket expenses and productivity 
losses were computed. A base case and sensitivity analyses were performed and the 
economic burden of pneumonia was determined using Philhealth claims. RESULTS: 
The estimated cost of hospitalization for CAP-MR was PhP 36,153 - 113,633 (US$852 
– 2,678) and the1-week post-discharge cost for CAP-MR was PhP 1,450 – 8,800 (US$ 
34 – 207) The cost of hospitalization for CAP-HR was PhP 104,544 – 249,695 (US$2,464 
– 5,885) and PhP 101,248 – 243, 495 (US$2,386 – 5,739) with the use of either invasive 
ventilation or non-invasive ventilation, respectively. The post discharge cost for 
CAP-HR was PhP 1,716 – 10,529 (US$40 – 248). In comparison, the present PhilHealth 
case rate payments for CAP-MR is PhP 15,000 (US$354) and PhP 32,000 (US$754) 
for CAP-HR. Based on the number of PhilHealth claims for the year 2012 and the 
study results, the economic burden of pneumonia in 2012 was PhP 8.48 billion for 
CAP-MR and PhP 643.76 million for CAP-HR. CONCLUSIONS: The paper reported the 
hospitalization and follow-up costs of CAP-MR and CAP-HR based on the societal 
perspective. It showed significant difference from the current case rate payments 
of the Philippine Health Insurance Corporation.
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OBJECTIVES: While it is known that accurate and timely diagnosis and treatment of 
infections can present a major healthcare challenge, there is a lack of in-depth studies 
examining infection diagnosis and treatment practices and their associated costs in 
large real-world patient populations. The study objective was to examine infection 
prevalence, current diagnosis and treatment practices, and costs associated with 
managing patients with infections via retrospective analysis of a large US electronic 
health record database. METHODS: Patients with infections were identified based 
on the use of antimicrobial therapy for > 24 h following hospital admission. Infection 
type was identified using ICD-9 diagnosis coding. Patients were classified into four 
groups: (1) pneumonia, (2) sepsis without pneumonia, (3) other infectious etiology, 
and (4) non-infectious etiology initially suspected as infectious. Illness severity was 
assessed using the Acute Physiology Score. Diagnostic procedures and treatments 
were identified via ICD-9 procedure coding and pharmacy order data, respectively. 
Per-patient cost estimates ($USD), calculated over 15 days from admission, encom-
passed diagnostic tests, radiologic procedures, and antimicrobial and other pharma-
ceutical treatments. RESULTS: In total, 127,174 patient visits met inclusion criteria. 
Pneumonia was the most common infection type (20.1% of visits), followed by other 
infectious etiology (16.0%) and sepsis without pneumonia (7.0%). Non-infections ini-
tially suspected as infections represented 56.9% of visits. Overall, 62.5% of patients 
had medium or high illness severity. Length-of-stay was > 5 days for 49.2% of patients. 
Bacterial tests accounted for 92.4% of diagnostic tests, and antibiotics accounted 
for the majority (> 98%) of antimicrobial treatments. Suspected infections with non-
infectious etiology had the highest per-patient costs for low-severity ($14,228) and 
medium-severity patients ($12,551). For high-severity patients, pneumonia carried the 
highest per-patient cost ($14,541). CONCLUSIONS: This study demonstrates that the 
total costs (in 2014 US dollars) were estimated for each urgent ABR threat, for each 
year analyzed. RESULTS: The number of CRE- and C. diff-related hospitalizations 
increased during the study period (CRE: 109,304 in 2001 to 692,680 in 2012; C. diff: 
144,312 in 2001 to 359,395 in 2012) but decreased for N. gonorrhoeae (5,440 in 2001 
to 4,130 in 2012). The mean LOS for all hospitalizations in the US between 2001-
2012 was 4.58 days and mean per-patient cost of $16,168. LOS for all urgent threats 
decreased over time (LOS: N. gonorrhoeae, 2001: 4.05 days, 2012: 3.92 days; CRE, 2001: 
10.15 days, 2012: 6.98 days; and C. diff, 2001: 13.53 days, 2012: 10.41 days) while total 
costs increased for N. gonorrhoeae, (2001: $9,963, 2012: $14,675) and C. diff(2001: 
$36,896, 2012: $43,632) but not for CRE (2001: $27,356, 2012: $26,959). CONCLUSIONS: 
Although LOS among ABR-related hospitalizations in the US has decreased over 
time, costs for both N. gonorrhoeae and C. diff have increased, +47% and +18%, 
respectively. Future efforts to reduce the incidence of ABR infection will improve 
the public’s health as well as decrease the associated economic burden.
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OBJECTIVES: To describe direct medical costs and factors associated with 
three disease stages of chronic hepatitis B virus infection (CHB) in Guangzhou, 
China. METHODS: We conducted a retrospective cohort study of patients with 
CHB using a hospital information system database from 2008 to 2012 in the larg-
est specialized infection hospital in Guangdong Province, China. Average annual 
costs and cost components were calculated. Generalized estimating equations were 
applied to explore associations between factors and costs. All costs were adjusted 
to RMB in 2012 at a discounting rate of 5% per year. RESULTS: A total of 65,792 (58 
455 outpatients and 7 337 inpatients) were involved in the analysis. Number of 
visits/admissions (mean) per case per year for outpatient and inpatient were as 
follows: CHB: 4.56/1.12; Cirrhosis: 4.34/1.24; HCC: 2.46/1.13; and the correspond-
ing average costs per person-time were: CHB: 581.79 and 8994.90 RMB; Cirrhosis: 
670.71 and 16574.44 RMB; HCC: 643.69 and 20900.89 RMB, respectively. Antiviral 
(47.93%) and non-antiviral medicines (34.44%, including 16.99% of liver protec-
tors and 6.31% of traditional Chinese medicine) for outpatient were the main cost 
components. Inpatient non-antiviral medicine and lab test contributed 45.56% and 
23.38% of total costs; but antiviral medicine was only at 6.28% of total costs. Male, 
elder, antiviral patients, cirrhosis and HCC patients had statistically significant 
higher costs as compared with female, younger, non-antiviral and CHB patients. 
Among the outpatients, self-payment patients’ costs were the highest, followed by 
patients with medical insurance and free medical service, whereas opposite effect 
direction on costs was found in inpatients, and the differences were statistically 
significant. CONCLUSIONS: Direct medical costs of inpatients with CHB increase 
significantly as the disease progresses. Payment mode has different effect direc-
tion between outpatient and inpatient, indicating that reimbursement policy for 
clinic and hospitalized patients have an important role on direct medical costs in 
treating HBV.
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OBJECTIVES: To assess the burden of and identify predictors of hospitalization costs 
associated with adverse drug events (ADEs) related to anti-infectives that were 
present on admission (POA) in US hospitals. Furthermore, we sought to identify dif-
ferences in costs by gender and age groups. METHODS: Using the 2012 Nationwide 
Inpatient Sample, we identified ADEs associated with anti-infectives using diagnosis 
codes (ICD-9-CM) and E codes. Differences in average and median hospitalization 
costs between subgroups were assessed using t-tests and Wilcoxon non-parametric 
median tests. To assess predictors of cost, we developed a generalized linear model 
(GLM) using the Modified Park test, Box-Cox regression test, Akaike information 
criterion and residual analysis to improve model fit. Results were weighted to obtain 
nationally representative cost estimates in 2012 dollars. RESULTS: Our study identi-
fied 49,623 discharges with POA ADEs (national estimate= 248,095) associated with 
anti-infectives with a total cost of $2.1 billion (national estimate= $10.6 billion). The 
mean cost for each hospitalization was $43,499 (SD= $76,865, median= $23,565, 
interquartile range= $13,189-$45,424) with a range $275 to $2,995,306. The mean 
length of stay (LOS) was 6.64 days (SD= 7.84, median= 5) and ranged from 0 to 354 
days. Total hospitalization costs were significantly (p= < .0001) higher for males 
(4.50%) and those aged 65 years or older (3.34%). GLM with gamma family and log 
link was a better model compared to ordinary least-squares. Using this model, we 
identified several significant cost predictors: LOS, age at admission, race, gender, 
median household income, hospital bed size and numerous comorbidities. Our 
model estimated that the cost of hospitalization, which was $67,528 for LOS of 
one day, increased 11.20% with each day increase in LOS. Each year increase in age 
caused 0.05% increase in hospitalization costs. CONCLUSIONS: Our findings sug-
gest that ADEs associated with anti-infectives are more costly when they occur in 
older patients and among those with medical comorbidities.
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